Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxcyte, Inc
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.
The former Operation Warp Speed leader has apologized unreservedly for his actions, and loses positions with two biopharma companies.
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- SutroVax, Inc.